tetano
Editor, Senior Moderator
doi: 10.3949/ccjm.79a.12151 Cleveland Clinic Journal of Medicine November 2012 vol. 79 11 777-784
Advertisement
Click here to find out more!
2012?2013 Influenza update: Hitting a rapidly moving target
XIAN WEN JIN, MD, PhD, FACP⇓a
Department of Internal Medicine, Medicine Institute, Cleveland Clinic
ADDRESS: Xian Wen Jin, MD, PhD, FACP, Department of Internal Medicine, G10, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail jinx@ccf.org.
SHERIF BENIAMEEN MOSSAD, MD, FACP, FIDSAb
+ Author Affiliations
Department of Infectious Diseases, Medicine Institute, Cleveland Clinic
Abstract
From the deadly 2009 influenza A H1N1 pandemic to the looming threat of bird flu H5N1, the recent outbreak of swine flu H3N2v at agriculture fairs, and the emergence of drug-resistant H1N1, we are constantly challenged by influenza viruses. Vaccination remains the main strategy for prevention. With the knowledge gained from past pandemics, an adequate vaccine supply, and an updated preventive strategy, we are in a better position to face the challenge.
Key points
A recent outbreak of swine flu in children exposed to pigs at agricultural fairs is unprecedented. Seasonal influenza vaccine does not protect against this strain, designated H3N2v. The neuraminidase inhibitors oseltamivir (Tamiflu) and zanamivir (Relenza) are the drugs of choice for treatment.
A highly lethal bird flu, designated H5N1, is still a pandemic threat. In the event of an outbreak, an inactivated whole-virus vaccine is available.
A community outbreak of oseltamivir-resistant H1N1 in Australia sounded an alarm for a potential drug-resistant flu epidemic. Inhaled zanamivir would be the only effective therapy available in the event of such an epidemic.
An emerging new antiviral drug is effective against oseltamivir-resistant influenza.
http://www.ccjm.org/content/79/11/777.short?rss=1
Advertisement
Click here to find out more!
2012?2013 Influenza update: Hitting a rapidly moving target
XIAN WEN JIN, MD, PhD, FACP⇓a
Department of Internal Medicine, Medicine Institute, Cleveland Clinic
ADDRESS: Xian Wen Jin, MD, PhD, FACP, Department of Internal Medicine, G10, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail jinx@ccf.org.
SHERIF BENIAMEEN MOSSAD, MD, FACP, FIDSAb
+ Author Affiliations
Department of Infectious Diseases, Medicine Institute, Cleveland Clinic
Abstract
From the deadly 2009 influenza A H1N1 pandemic to the looming threat of bird flu H5N1, the recent outbreak of swine flu H3N2v at agriculture fairs, and the emergence of drug-resistant H1N1, we are constantly challenged by influenza viruses. Vaccination remains the main strategy for prevention. With the knowledge gained from past pandemics, an adequate vaccine supply, and an updated preventive strategy, we are in a better position to face the challenge.
Key points
A recent outbreak of swine flu in children exposed to pigs at agricultural fairs is unprecedented. Seasonal influenza vaccine does not protect against this strain, designated H3N2v. The neuraminidase inhibitors oseltamivir (Tamiflu) and zanamivir (Relenza) are the drugs of choice for treatment.
A highly lethal bird flu, designated H5N1, is still a pandemic threat. In the event of an outbreak, an inactivated whole-virus vaccine is available.
A community outbreak of oseltamivir-resistant H1N1 in Australia sounded an alarm for a potential drug-resistant flu epidemic. Inhaled zanamivir would be the only effective therapy available in the event of such an epidemic.
An emerging new antiviral drug is effective against oseltamivir-resistant influenza.
http://www.ccjm.org/content/79/11/777.short?rss=1